Related Experiment Video
Updated: May 23, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
[Glucagon-like peptide-1 agonists and heart failure]
Nisha Soborun1, Lucie Favre2, Henri Lu1
1Service de cardiologie, Département cœur-vaisseaux, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue Medicale Suisse
|May 22, 2026
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show cardiovascular benefits in diabetes and obesity. Recent studies highlight their effectiveness in heart failure patients, improving symptoms and reducing hospitalizations.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed for type 2 diabetes.
- GLP-1 RAs have demonstrated cardiovascular benefits in patients with diabetes and obesity.
- Emerging data suggest efficacy in heart failure (HF) patients.
Purpose of the Study:
- To summarize current evidence on GLP-1 RAs in heart failure.
- To provide practical guidance for prescribing and monitoring GLP-1 RAs in HF patients.
Main Methods:
- Review of current scientific literature on GLP-1 RAs and cardiovascular outcomes.
- Analysis of recent clinical trial data focusing on heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF).
Main Results:
- GLP-1 RAs, including semaglutide and tirzepatide, show benefits in obese patients with HFpEF/HFmrEF.
- Observed benefits include reduced HF hospitalizations and improved symptoms and functional capacity.
- Limited data currently exist for heart failure with reduced ejection fraction (HFrEF).
Conclusions:
- GLP-1 RAs represent a promising therapeutic option for specific heart failure populations.
- Further research is needed to establish their role in HFrEF.
- Clinical guidance for use in HF patients is evolving.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...